Welcome to our dedicated page for Ultragenyx Pharmaceutical news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharmaceutical stock.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), founded in 2010, is a clinical-stage biotechnology company dedicated to developing and commercializing innovative therapies for the treatment of serious rare and ultra-rare genetic diseases. The company’s core focus is on debilitating metabolic genetic diseases, for which there are high unmet medical needs, and the biology for treatment is well-understood but lacks approved therapies. Ultragenyx's management team brings extensive experience in rare disease therapeutics.
The company’s diverse product portfolio includes approved medicines like Crysvita, Dojolvi, and Mepsevii. Crysvita is designed for the treatment of X-linked hypophosphatemia (XLH), a rare genetic bone disease, and has shown significant growth with revenue reaching $328 million in 2023. Dojolvi targets long-chain fatty acid oxidation disorders and saw a 27% revenue increase in 2023. Mepsevii treats Mucopolysaccharidosis VII, another severe genetic disorder.
Recent Achievements and Financial Performance
In 2023, Ultragenyx reported total revenues of $434 million, a 20% increase from the previous year. The company has a robust pipeline with several candidates in late-stage clinical trials. For instance, the Phase 3 Orbit study for UX143 (setrusumab) in Osteogenesis Imperfecta (OI) completed enrollment and showed promising interim results with a 67% reduction in fracture rates.
Ongoing Projects
- GTX-102: An antisense oligonucleotide for Angelman syndrome showed significant improvements in clinical trials, with plans for a Phase 3 study in 2024.
- UX701: A gene therapy for Wilson disease, with data expected in mid-2024.
- DTX401: A gene therapy for Glycogen Storage Disease Type Ia (GSDIa), achieved its primary endpoint in a Phase 3 study.
- Setrusumab (UX143): Demonstrated significant fracture rate reduction and bone mineral density improvement in OI patients.
Partnerships and Collaborations
Ultragenyx collaborates with various regulatory bodies and advocacy groups to support patients and ensure high-quality clinical trials. The company’s partnership with Mereo BioPharma on setrusumab exemplifies its collaborative approach to drug development.
Corporate Responsibility
Ultragenyx's 2023 Corporate Responsibility Report highlights its commitment to innovation, patient support, diversity, and environmental sustainability. The company has been recognized with several awards, including the Top Places to Work by the Boston Globe and Healthcare’s Best Companies to Work by U.S. News & World Report.
For more information, visit www.ultragenyx.com.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:40 PM ET. Key executives, including Chief Medical Officer Camille Bedrosian and Chief Financial Officer Mardi Dier, will lead the presentation. Interested parties can access the live and archived webcast on the company's website for 90 days following the event. Ultragenyx is dedicated to developing innovative therapies for rare and ultra-rare genetic diseases, with a focus on addressing high unmet medical needs.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its upcoming conference call scheduled for May 5, 2022, at 5:00 PM ET to discuss financial results for Q1 2022. The call will provide updates on the company's performance and strategy in treating rare genetic diseases. Investors can participate via phone or access a live and recorded webcast on the company’s website. Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic disorders, emphasizing time-efficient drug development to meet patient needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) has appointed Amrit Ray, M.D., M.B.A., to its Board of Directors, specifically on the Research and Development Committee. Dr. Ray brings extensive experience as a physician researcher and executive, previously serving as Chief Patient Officer at Biohaven Pharmaceuticals and holding senior roles at Pfizer and Johnson & Johnson. His expertise is expected to enhance Ultragenyx's commitment to developing innovative treatments for rare diseases. The company focuses on delivering novel therapeutic products to address significant unmet medical needs.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the initiation of the global Orbit study, a pivotal Phase 2/3 trial for UX143 to treat Osteogenesis Imperfecta (OI) in patients aged 5 to <26. This study follows the promising results of the Phase 2b ASTEROID study, which showed significant improvements in bone density. The Orbit study aims to assess fracture risk reduction in younger populations, with plans for additional studies in other age groups. The collaboration with Mereo BioPharma continues to support the development of UX143 for OI.
Ultragenyx Pharmaceutical (NASDAQ: RARE) will have its CEO, Emil D. Kakkis, participate in the Orphan CNS Panel at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 2:10 PM ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days. Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at addressing high unmet medical needs. The management team is dedicated to efficient drug development to deliver safe and effective therapies rapidly.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported total revenue of $351.4 million for 2021, with $192.6 million from Crysvita. The company anticipates Crysvita revenue between $250 million and $260 million for 2022. Dojolvi revenue guidance is $55 million to $65 million. The year-end cash balance stands at $1.0 billion. Despite revenue growth, Ultragenyx posted a net loss of $454 million, or $6.70 per share, reflecting increased operating expenses. The company is focused on expanding its clinical pipeline and commercializing Evkeeza in Europe.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on February 10, 2022, at 5:00 PM ET to discuss its financial results for Q4 and the full year ended December 31, 2021. The call will detail the company’s performance and corporate updates. A live and replayed webcast will be accessible on the company’s website, ensuring transparency regarding its operations in developing therapies for rare diseases. Ultragenyx focuses on addressing high unmet medical needs with its innovative therapies.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options for 16,050 shares and 5,350 restricted stock units to two newly hired non-executive officers. These awards, approved by the board's compensation committee, were made under the Ultragenyx Employment Inducement Plan as an inducement to the new hires. The options vest over four years with a starting exercise price of $72.04, equal to the closing stock price on February 1, 2022. The company focuses on developing therapies for rare diseases, aiming for rapid and efficient drug development.
ShouTi Inc., a clinical-stage biopharmaceutical firm, has appointed Daniel Welch as Chairman of its board. Welch brings over 40 years of experience in the pharmaceutical industry, having led companies like InterMune and Triangle Pharmaceuticals. His extensive background in drug development is expected to bolster ShouTi's mission to deliver innovative, small molecule medicines addressing chronic diseases. CEO Raymond Stevens emphasized Welch's invaluable leadership as the company seeks to enhance its impact on patients awaiting life-changing treatments.
FAQ
What is the current stock price of Ultragenyx Pharmaceutical (RARE)?
What is the market cap of Ultragenyx Pharmaceutical (RARE)?
What is the primary focus of Ultragenyx Pharmaceutical Inc.?
What are some key products of Ultragenyx?
What were the financial highlights for Ultragenyx in 2023?
What recent achievements has Ultragenyx made in clinical trials?
Who leads Ultragenyx Pharmaceutical Inc.?
What partnerships does Ultragenyx have?
What is Ultragenyx's commitment to corporate responsibility?
How does Ultragenyx engage with the rare disease community?
What are the future plans for GTX-102?
Where can I find more information about Ultragenyx?
